Skip to content

Study · In vitro (cell-free) · 1993

3 results

Modulation of the interaction between G-actin and thymosin beta 4 by the ATP/ADP ratio: possible implication in the regulation of actin dynamics.

Carlier MF, Jean C, Rieger KJ, Lenfant M, Pantaloni D

Proceedings of the National Academy of Sciences of the United States of America1 Jun 1993Cited by 112 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cell-free)Activity measurement

    In vitro, thymosin beta‑4 had a 50-fold higher affinity for MgATP-actin than for MgADP-actin.

    In plain wordsIn lab tests, thymosin beta‑4 bound ATP-actin about 50 times more strongly than ADP-actin.

    Outcome
    Not applicableAffinity for MgATP-actin versus MgADP-actin
    Study

    n: not reported in source

    In vitro G-actin and thymosin beta 4 binding
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Affinity ratio MgATP-actin versus MgADP-actin
    50 fold
    thymosin beta 4

    Source sentences

    Summary
    T beta 4 is found to have a 50-fold higher affinity for MgATP-actin than for MgADP-actin.
    1 context sentence
    Summary · context
    The interaction of G-actin with thymosin beta 4 (T beta 4), the major G-actin-sequestering protein in motile and proliferating cells, has been analyzed in vitro.
  2. 02LabIn vitro (cell-free)Mechanism

    In vitro, kinetic experiments and calculations showed that the ATP/ADP dependence of thymosin beta‑4 affinity for G-actin can generate desequestration of G-actin by ADP at physiological thymosin beta‑4 concentrations.

    In plain wordsIn lab tests and calculations, ADP could release actin from thymosin beta‑4 at levels found in cells.

    Outcome
    Not applicableG-actin desequestration by ADP
    Study

    n: not reported in source

    In vitro G-actin and thymosin beta 4 binding
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Kinetic experiments and theoretical calculations demonstrate that this ATP/ADP dependence of T beta 4 affinity for G-actin can generate a mechanism of desequestration of G-actin by ADP, in the presence of physiological concentrations of T beta 4 (approximately 0.1 mM).
    1 context sentence
    Summary · context
    The interaction of G-actin with thymosin beta 4 (T beta 4), the major G-actin-sequestering protein in motile and proliferating cells, has been analyzed in vitro.

Studies that did not test the peptide alone1

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 03LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Mechanism

    In vitro, profilin kinetically enhanced the desequestration of G-actin by ADP, since it accelerates the dissociation of ATP from G-actin.

    In plain wordsIn lab tests, profilin sped up the release of actin from thymosin beta‑4 by ADP.

    Outcome
    IncreaseEffect of profilin on desequestration of G-actin by ADP
    Study

    n: not reported in source

    In vitro G-actin and thymosin beta 4 binding
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    The desequestration of G-actin by ADP is kinetically enhanced by profilin, which accelerates the dissociation of ATP from G-actin.
    1 context sentence
    Summary · context
    The interaction of G-actin with thymosin beta 4 (T beta 4), the major G-actin-sequestering protein in motile and proliferating cells, has been analyzed in vitro.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.